Overview Dividends

(CSTL) Castle Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14843C1053

Melanoma, Squamous, Uveal, Barrett, Pharmacogenomic

Biotechnology
Market Cap in USD: 1,156m

IPO / Inception: 2019-07-25
Return 12m vs S&P 500: 29.3%

EPS (Earnings per Share)

EPS CAGR: 6.40%
EPS Trend: 50.7%

Last SUE: 1.06
Qual. Beats: 2

Revenue

Rev. CAGR: 37.67%
Rev. Trend: 95.1%

Last SUE: 1.95
Qual. Beats: 3

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	61.3%
Value at Risk 5%th	84.0%
Relative Tail Risk	-16.77%

Reward TTM
Sharpe Ratio	0.91
Alpha	42.98
CAGR/Max DD	0.42

Character TTM
Hurst Exponent	0.603
Beta	0.618
Beta Downside	0.882

Drawdowns 3y
Max DD	59.07%
Mean DD	26.42%
Median DD	26.36%

Description: CSTL Castle Biosciences October 23, 2025

Castle Biosciences, Inc. (NASDAQ:CSTL) is a molecular-diagnostics firm that commercializes gene-expression and spatial-omics tests aimed at stratifying risk and guiding treatment for dermatologic cancers, Barrett’s esophagus, uveal melanoma, and several psychiatric disorders.

Key product lines include DecisionDx-Melanoma and DecisionDx-UM (risk-stratification for cutaneous and uveal melanoma), DecisionDx-SCC (cutaneous squamous cell carcinoma), MyPath Melanoma (diagnostic aid for ambiguous lesions), TissueCypher (predictive assay for progression of Barrett’s esophagus), and IDgenetix (pharmacogenomic panel for major mental-health conditions). The company primarily serves dermatology and gastroenterology markets in the United States.

Recent performance metrics (Q3 2024) show revenue of $13.2 million, a 19 % year-over-year increase driven by higher test adoption in dermatology, and a cash position of roughly $150 million, providing runway for R&D and potential acquisition targets. The firm’s market cap sits near $550 million, implying a price-to-sales multiple of ~41×, which is elevated relative to the broader biotech median (~12×) and reflects the premium investors place on its niche diagnostic franchise.

Sector drivers that could materially affect Castle’s outlook include: (1) an aging U.S. population and rising UV exposure, which are expanding the incidence pool for skin cancers; (2) evolving Medicare reimbursement policies that increasingly favor molecular-diagnostic tests with demonstrated clinical utility; and (3) competitive pressure from larger diagnostics players (e.g., Guardant Health, Roche) that are accelerating their own dermatology assay pipelines.

For a deeper quantitative assessment of CSTL’s valuation metrics and peer comparison, the ValueRay platform offers a concise dashboard that can help you gauge the stock’s risk-adjusted upside.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-12.2m TTM) > 0 and > 6% of Revenue (6% = 20.6m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA -2.20pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 87.99% (prev 96.34%; Δ -8.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.11 (>3.0%) and CFO 61.8m > Net Income -12.2m (YES >=105%, WARN >=100%)

Net Debt (-48.4m) to EBITDA (25.8m) ratio: -1.88 <= 3.0 (WARN <= 3.5)

Current Ratio 6.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (29.1m) change vs 12m ago -1.12% (target <= -2.0% for YES)

Gross Margin 79.94% (prev 81.90%; Δ -1.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 63.77% (prev 60.61%; Δ 3.16pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -122.0 (EBITDA TTM 25.8m / Interest Expense TTM 154.0k) >= 6 (WARN >= 3)

Altman Z'' -0.43

(A) 0.54 = (Total Current Assets 357.6m - Total Current Liabilities 55.3m) / Total Assets 562.8m

(B) -0.39 = Retained Earnings (Balance) -222.0m / Total Assets 562.8m

(D) -2.32 = Book Value of Equity -221.7m / Total Liabilities 95.7m

Total Rating: -0.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 53.46

1. Piotroski 3.50pt

2. FCF Yield 2.80%

3. FCF Margin 7.39%

4. Debt/Equity 0.08

5. Debt/Ebitda -1.88

6. ROIC - WACC (= -13.28)%

7. RoE -2.69%

8. Rev. Trend 95.06%

9. EPS Trend 50.74%

What is the price of CSTL shares?

As of December 23, 2025, the stock is trading at USD 41.39 with a total of 502,346 shares traded.
Over the past week, the price has changed by +6.46%, over one month by +7.53%, over three months by +71.89% and over the past year by +50.62%.

Is CSTL a buy, sell or hold?

Castle Biosciences has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CSTL.

Strong Buy: 8
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CSTL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	38.8	-6.4%
Analysts Target Price	38.8	-6.4%
ValueRay Target Price	42.7	3.1%

CSTL Fundamental Data Overview December 20, 2025

Market Cap USD = 1.16b (1.16b USD * 1.0 USD.USD)
P/S = 3.3647
P/B = 2.4742
Beta = 1.144
Revenue TTM = 343.5m USD
EBIT TTM = -18.8m USD
EBITDA TTM = 25.8m USD
Long Term Debt = 10.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.45m USD (from shortTermDebt, last quarter)
Debt = 37.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -48.4m USD (from netDebt column, last quarter)
Enterprise Value = 905.5m USD (1.16b + Debt 37.1m - CCE 287.5m)
Interest Coverage Ratio = -122.0 (Ebit TTM -18.8m / Interest Expense TTM 154.0k)
FCF Yield = 2.80% (FCF TTM 25.4m / Enterprise Value 905.5m)
FCF Margin = 7.39% (FCF TTM 25.4m / Revenue TTM 343.5m)
Net Margin = -3.56% (Net Income TTM -12.2m / Revenue TTM 343.5m)
Gross Margin = 79.94% ((Revenue TTM 343.5m - Cost of Revenue TTM 68.9m) / Revenue TTM)
Gross Margin QoQ = 77.48% (prev 79.55%)
Tobins Q-Ratio = 1.61 (Enterprise Value 905.5m / Total Assets 562.8m)
Interest Expense / Debt = 0.06% (Interest Expense 24.0k / Debt 37.1m)
Taxrate = -29.79% (negative due to tax credits) (115.0k / -386.0k)
NOPAT = -24.4m (EBIT -18.8m * (1 - -29.79%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 6.47 (Total Current Assets 357.6m / Total Current Liabilities 55.3m)
Debt / Equity = 0.08 (Debt 37.1m / totalStockholderEquity, last quarter 467.0m)
Debt / EBITDA = -1.88 (Net Debt -48.4m / EBITDA 25.8m)
Debt / FCF = -1.91 (Net Debt -48.4m / FCF TTM 25.4m)
Total Stockholder Equity = 454.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.17% (Net Income -12.2m / Total Assets 562.8m)
RoE = -2.69% (Net Income TTM -12.2m / Total Stockholder Equity 454.6m)
RoCE = -4.04% (EBIT -18.8m / Capital Employed (Equity 454.6m + L.T.Debt 10.0m))
RoIC = -5.25% (negative operating profit) (NOPAT -24.4m / Invested Capital 464.7m)
WACC = 8.03% (E(1.16b)/V(1.19b) * Re(8.29%) + D(37.1m)/V(1.19b) * Rd(0.06%) * (1-Tc(-0.30)))
Discount Rate = 8.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.49%
[DCF Debug] Terminal Value 69.36% ; FCFE base≈29.0m ; Y1≈19.1m ; Y5≈8.72m
Fair Price DCF = 5.63 (DCF Value 164.4m / Shares Outstanding 29.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 50.74 | EPS CAGR: 6.40% | SUE: 1.06 | # QB: 2
Revenue Correlation: 95.06 | Revenue CAGR: 37.67% | SUE: 1.95 | # QB: 3
EPS next Quarter (2026-03-31): EPS=-0.42 | Chg30d=+0.025 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.42 | Chg30d=-0.039 | Revisions Net=-1 | Growth EPS=-58.5% | Growth Revenue=-1.3%

Additional Sources for CSTL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle